CompletedPhase 3NCT00301366

The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 14, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Grifols Therapeutics LLC
Principal Investigator: Kim Hanna, MSc
Grifols Therapeutics LLC
Intervention: alpha-1 proteinase inhibitor (human)(drug)
Enrollment: 38 enrolled
Eligibility: 18 years · All sexes
Timeline: 2006 – 2007

Study locations (10)

National Jewish Medical and Research Center, Denver, Colorado, United States
University of Florida College of Medicine, Gainesville, Florida, United States
University of Miami School of Medicine, Miami, Florida, United States
St Lukes-Roosevelt Hospital Center, New York, New York, New York, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Temple University Hospital, Philadelphia, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
University of Texas Health Center at Tyler, Tyler, Texas, United States
University of Cambridge - Cambridge Institute for Medical Research, Cambridge, England, United Kingdom
University Teaching Hospital of Edinburgh, Edinburgh, Scotland, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00301366 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials